Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland

Lynda M. McSorley,Mehala Tharmabala,Fathiya Al Rahbi,Fergus Keane,Denis Evoy,James G. Geraghty,Jane Rothwell,Damian P. McCartan,Megan Greally,Miriam O’Connor,Deirdre O’Mahony,Maccon Keane,Michael John Kennedy,Seamus O’Reilly,Steve J. Millen,John P. Crown,Catherine M. Kelly,Ruth S. Prichard,Cecily M. Quinn,Janice M. Walshe,Miriam O'Connor,Deirdre O'Mahony,Seamus O'Reilly

DOI: https://doi.org/10.3390/curroncol31030098

2024-03-02

Current Oncology

Abstract:Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer patients. All patients had ILC and had RS testing in Ireland. The patient population is representative of the national population. Patients were classified as low (RS ≤ 25) or high (RS > 25) risk. Patients aged ≤50 were stratified as low (RS 0–15), intermediate (RS 16–25), or high risk (RS > 25). Results: A total of 168 patients were included, most of whom had grade 2 (G2) tumors (n = 154, 92%). Overall, 155 patients (92.3%) had low RS (≤25), 12 (7.1%) had high RS (>25), and 1 (0.6%) had unknown RS status. In 29 (17.5%) patients aged ≤50 at diagnosis, RS was ≤15 in 16 (55%), 16–20 in 6 (21%), 21–25 in 5 (17%), >25 in 1 (3.5%), and unknown in 1 (3.5%). Post RS testing, 126 patients (78%) had a change in chemotherapy recommendation; all to hormone therapy. In total, only 35 patients (22%) received chemotherapy. RS testing achieved a 75% reduction in chemotherapy use, resulting in savings of €921,543.84 in treatment costs, and net savings of €387,283.84. Conclusions: The use of this test resulted in a 75% reduction in chemotherapy and a significant cost savings in our publicly funded health system.

oncology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to evaluate the clinical and economic impacts of the 21 - gene Recurrence Score (RS) test in Irish patients with early - invasive lobular breast carcinoma (ILC). Specifically, the research objectives include:

1. **Changes in treatment pathways**: Evaluate the impact of the RS test on chemotherapy recommendations, especially whether it reduces the use of unnecessary chemotherapy.
2. **Economic impact**: Analyze the cost savings brought by the RS test in the publicly - funded healthcare system.

### Research background

- **Overview of breast cancer**: Breast cancer is the most common cancer in women, with more than 3,000 new diagnosed cases in Ireland every year. Although the survival rate of early - breast cancer is relatively high (the 5 - year survival rate is 82%), it is still the second leading cause of cancer - related deaths in women.
- **Characteristics of ILC**: Lobular breast carcinoma (ILC) accounts for approximately 10 - 15% of all breast cancers. It is characterized by positive hormone receptors, low tumor grade, and a relatively low proliferation rate. However, long - term survival data show that ILC loses its early - stage advantage after about 10 years, and the risk of late - stage recurrence increases.
- **Effectiveness of chemotherapy**: Adjuvant chemotherapy has limited effectiveness in ILC and cannot significantly improve cancer - specific survival rates. Therefore, it is particularly important to guide treatment decisions through gene expression profiles (such as the 21 - gene test).

### Research methods

- **Research design**: This is a retrospective observational study, and the data collection period was from 2011 to 2019.
- **Research subjects**: 168 patients with early - stage ILC who were lymph - node - negative, hormone - receptor - positive (HR+), and HER2 - negative were included.
- **Data sources**: Data were obtained from electronic medical records and paper medical records, including patients' age, tumor size, lymphatic vessel invasion (LVI), lymph - node status, AJCC staging, and RS results.
- **Treatment decisions**: The type of surgery (breast - conserving surgery or mastectomy) for each patient, whether they received adjuvant treatment, and the changes in treatment recommendations after the RS test were recorded.

### Main results

- **Changes in treatment pathways**: Among the 168 patients, 126 (78%) patients had their chemotherapy recommendations changed after the RS test, from chemotherapy to only receiving endocrine treatment. Eventually, only 35 (22%) patients received chemotherapy.
- **Economic impact**: The RS test led to a 75% reduction in chemotherapy use, saving €921,543.84 in treatment costs and a net saving of €387,283.84.

### Conclusions

- **Clinical impact**: The 21 - gene test significantly reduces the use of unnecessary chemotherapy and improves patients' treatment decisions.
- **Economic impact**: In the publicly - funded healthcare system, the 21 - gene test brings significant cost savings.
- **Future research directions**: Further research is needed to more comprehensively elucidate the role of chemotherapy or targeted therapy in ILC and the optimal application of genomic testing in this disease subtype.

### Formulas and symbol explanations

- **Net percentage reduction**: \[ \text{Net percentage reduction} = \left( \frac{\text{The number of patients who actually received chemotherapy}}{\text{The number of patients expected to receive chemotherapy without RS test}} \right) \times 100\% \]
- **Total cost calculation**: \[ \text{Total cost} = (\text{Number of patients} \times \text{Cost of each 21 - gene test}) - (\text{Net reduction in chemotherapy} \times \text{Number of patients} \times \text{Cost of chemotherapy}) \]

It is hoped that this information will help you better understand the content and significance of this paper. If you have any other questions or need further explanations, please feel free to let me know.